Aurobindo Pharma Reports Record Revenue and Approves Subsidiary Merger

Aurobindo Pharma reported a 25.2% year-on-year increase in consolidated net profit to ₹1,032 crore for the first quarter ended June 30, 2026. The company achieved record quarterly revenue of ₹9,150 crore, representing a 16.3% increase. This growth was primarily driven by a 16.5% rise in formulations revenue to ₹8,101 crore, with gains in the U.S. and Europe, while total API revenue grew 14.6% to ₹1,049 crore.

In a strategic organizational move, the company's Board approved the merger of three wholly owned step-down subsidiaries: Eugia Steriles, Eugia SEZ, and Eugia Pharma Specialities. The amalgamation of these injectable pharmaceutical manufacturing arms aims to simplify the group structure and lower corporate overheads.

Vice-Chairman and Managing Director K. Nithyananda Reddy attributed the results to disciplined execution and a diversified product portfolio. Reddy stated that the company's resilient business model and strategic investments position it to achieve long-term growth objectives despite a dynamic global operating environment.